At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 206 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4, Double-blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction With Surgery in Subjects With Moderate to Severe Hidradenitis Suppurativa
In Brief
A Phase 4 clinical trial evaluating Placebo and Adalimumab for Hidradenitis Suppurativa (HS). Completed, enrolled 206 participants across 55 sites in 23 countries.
Detailed Summary
The objective of this study was to assess the safety and efficacy of adalimumab prior to surgery in participants with moderate to severe Hidradenitis Suppurativa (HS) who were surgical candidates.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHidradenitis Suppurativa (HS)
CountriesBelgium, Canada, Colombia, Czechia, Denmark, France, Germany, Greece, Ireland, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russia, Saudi Arabia, Spain, Sweden, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartJul 2016
Primary CompletionMay 2019
Study CompletionOct 2019
TodayJul 2026
First PostedJun 22, 2016
Enrollment StartJul 18, 2016
Primary CompletionMay 16, 2019
Study CompletionOct 16, 2019
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 10.0 years ago
Interventions
Placebodrug
Subcutaneous injections administered as described in arm description
Adalimumabdrug
Subcutaneous injections administered as described in arm description